The New England journal of medicine
-
Comment Letter
Removal of Small, Asymptomatic Kidney Stones and Relapse.
-
Randomized Controlled Trial
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Psilocybin is being studied for use in treatment-resistant depression. ⋯ In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder. (Funded by COMPASS Pathfinder; EudraCT number, 2017-003288-36; ClinicalTrials.gov number, NCT03775200.).